| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 979K | 462K | 2.72M | 0 | 0 | 1.03M |
| Revenue Growth % | - | -0.53% | 4.88% | -1% | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 822K | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 979K | 462K | 2.72M | 0 | -822K | 1.03M |
| Gross Margin % | 1% | 1% | 1% | - | - | 1% |
| Gross Profit Growth % | - | -0.53% | 4.88% | -1% | - | 2.25% |
| Operating Expenses | 28.04M | 17.01M | 54.32M | 63.45M | 65.28M | 54.34M |
| OpEx % of Revenue | 28.65% | 36.81% | 19.99% | - | - | 52.86% |
| Selling, General & Admin | 3.46M | 4.96M | 27.83M | 26.84M | 26.48M | 23.95M |
| SG&A % of Revenue | 3.54% | 10.74% | 10.24% | - | - | 23.29% |
| Research & Development | 24.58M | 12.04M | 26.48M | 36.61M | 39.62M | 26.68M |
| R&D % of Revenue | 25.11% | 26.07% | 9.75% | - | - | 25.96% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -822K | 3.71M |
| Operating Income | -27.07M | -16.54M | -51.6M | -63.45M | -66.1M | -53.31M |
| Operating Margin % | -27.65% | -35.81% | -18.99% | - | - | -51.86% |
| Operating Income Growth % | - | 0.39% | -2.12% | -0.23% | -0.04% | 0.19% |
| EBITDA | -26.5M | -15.96M | -51.1M | -62.9M | -65.28M | -52.29M |
| EBITDA Margin % | -27.07% | -34.53% | -18.81% | - | - | -50.86% |
| EBITDA Growth % | - | 0.4% | -2.2% | -0.23% | -0.04% | 0.2% |
| D&A (Non-Cash Add-back) | 564K | 589K | 497K | 548K | 822K | 1.03M |
| EBIT | -26.58M | -16.54M | -52.58M | -62.2M | -66.1M | -51.55M |
| Net Interest Income | 413K | -61K | -377K | 177K | -1.78M | -3.27M |
| Interest Income | 423K | 63K | 89K | 1.25M | 3.3M | 1.76M |
| Interest Expense | 10K | 124K | 466K | 1.07M | 5.08M | 5.03M |
| Other Income/Expense | 478K | -124K | -1.45M | 177K | -1.78M | 23.3M |
| Pretax Income | -26.59M | -16.67M | -53.05M | -63.27M | -67.88M | -30.02M |
| Pretax Margin % | -27.16% | -36.08% | -19.52% | - | - | -29.2% |
| Income Tax | 0 | 35K | 41K | 70K | 0 | 26.57M |
| Effective Tax Rate % | 1% | 1% | 0.16% | 0.48% | 0.5% | 1% |
| Net Income | -26.6M | -16.7M | -8.33M | -30.59M | -33.97M | -30.02M |
| Net Margin % | -27.17% | -36.15% | -3.07% | - | - | -29.2% |
| Net Income Growth % | - | 0.37% | 0.5% | -2.67% | -0.11% | 0.12% |
| Net Income (Continuing) | -26.59M | -16.7M | -53.09M | -63.34M | -67.88M | -56.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 74.16M | 37.15M | 12.58M | 1.5M |
| EPS (Diluted) | -1.35 | -0.85 | -0.42 | -1.28 | -1.33 | -1.05 |
| EPS Growth % | - | 0.37% | 0.51% | -2.05% | -0.04% | 0.21% |
| EPS (Basic) | -1.35 | -0.85 | -0.42 | -1.28 | -1.33 | -1.05 |
| Diluted Shares Outstanding | 18.74M | 18.74M | 19.53M | 23.82M | 25.5M | 28.48M |
| Basic Shares Outstanding | 18.74M | 18.74M | 19.53M | 23.82M | 25.5M | 28.48M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 16.94M | 74.94M | 119.59M | 100.92M | 50.85M | 29.74M |
| Cash & Short-Term Investments | 16.54M | 73.06M | 117.45M | 98.48M | 48.54M | 27.64M |
| Cash Only | 16.54M | 73.06M | 117.45M | 27.01M | 5.86M | 3.76M |
| Short-Term Investments | 0 | 0 | 0 | 71.47M | 42.67M | 23.88M |
| Accounts Receivable | 250K | 1.72M | 0 | 0 | 200K | 428K |
| Days Sales Outstanding | 93.21 | 1.36K | - | - | - | 151.97 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 500K | 800K | 1.68M |
| Total Non-Current Assets | 6.08M | 4.47M | 4.61M | 7.1M | 7.07M | 6.89M |
| Property, Plant & Equipment | 4.45M | 4.47M | 4.61M | 7.1M | 6.82M | 6.64M |
| Fixed Asset Turnover | 0.22x | 0.10x | 0.59x | - | - | 0.15x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 1.63M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 246K | 246K |
| Total Assets | 23.02M | 79.42M | 124.21M | 108.03M | 57.92M | 36.63M |
| Asset Turnover | 0.04x | 0.01x | 0.02x | - | - | 0.03x |
| Asset Growth % | - | 2.45% | 0.56% | -0.13% | -0.46% | -0.37% |
| Total Current Liabilities | 3.5M | 5.31M | 2.64M | 4.82M | 7.99M | 19.89M |
| Accounts Payable | 198K | 537K | 1.08M | 1.46M | 648K | 1.36M |
| Days Payables Outstanding | - | - | - | - | 287.74 | - |
| Short-Term Debt | 0 | 1.36M | 0 | 0 | 4.9M | 15M |
| Deferred Revenue (Current) | 179K | 1000K | 0 | 0 | 1000K | 0 |
| Other Current Liabilities | 601K | 88K | 126K | 591K | 202K | 283K |
| Current Ratio | 4.84x | 14.12x | 45.30x | 20.96x | 6.36x | 1.50x |
| Quick Ratio | 4.84x | 14.12x | 45.30x | 20.96x | 6.36x | 1.50x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 116.16M | 187.45M | 1 | 29.21M | 24.48M | 13.25M |
| Long-Term Debt | 115.5M | 2.41M | 0 | 29.15M | 24.48M | 9.61M |
| Capital Lease Obligations | 0 | 0 | 0 | 59K | 0 | 3.64M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 655K | 185.03M | 1 | 0 | 0 | 0 |
| Total Liabilities | 119.66M | 192.75M | 2.64M | 34.02M | 32.47M | 33.14M |
| Total Debt | 115.5M | 3.77M | 0 | 30.21M | 30.1M | 29.71M |
| Net Debt | 98.97M | -69.29M | -117.45M | 3.21M | 24.23M | 25.95M |
| Debt / Equity | - | - | - | 0.41x | 1.18x | 8.51x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -2706.50x | -133.42x | -110.73x | -59.24x | -13.00x | -10.59x |
| Total Equity | -96.64M | -113.34M | 121.57M | 74M | 25.44M | 3.49M |
| Equity Growth % | - | -0.17% | 2.07% | -0.39% | -0.66% | -0.86% |
| Book Value per Share | -5.16 | -6.05 | 6.22 | 3.11 | 1.00 | 0.12 |
| Total Shareholders' Equity | -96.64M | -113.34M | 47.41M | 36.85M | 12.87M | 1.99M |
| Common Stock | 664K | 664K | 5K | 5K | 5K | 5K |
| Retained Earnings | -97.3M | -114M | -8.33M | -38.92M | -72.89M | -102.91M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -780.16K | -849.03K | 0 | -73K | -12K | 5K |
| Minority Interest | 0 | 0 | 74.16M | 37.15M | 12.58M | 1.5M |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -26.27M | -14.96M | -32.24M | -46.52M | -51.24M | -35.5M |
| Operating CF Margin % | -26.83% | -32.38% | -11.87% | - | - | -34.53% |
| Operating CF Growth % | - | 0.43% | -1.16% | -0.44% | -0.1% | 0.31% |
| Net Income | -26.59M | -16.7M | -8.33M | -63.34M | -33.97M | -56.58M |
| Depreciation & Amortization | 564K | 589K | 497K | 548K | 822K | 1.03M |
| Stock-Based Compensation | 0 | 0 | 22.59M | 15.78M | 19.01M | 16.03M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -81K | 110K | -43.58M | -10K | -34.96M | 4.57M |
| Working Capital Changes | -163K | 1.04M | -3.43M | 509K | -2.14M | -544K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | -428K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -271K | 933K | 543K | 163K | -595K | 711K |
| Cash from Investing | -1.53M | -1.2M | -506K | -72.44M | 29.86M | 19.81M |
| Capital Expenditures | -1.58M | -1.2M | -506K | -1.62M | -1.23M | -268K |
| CapEx % of Revenue | 1.61% | 2.6% | 0.19% | - | - | 0.26% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 851K | 0 | 1.25M |
| Cash from Financing | 852K | 72.68M | 77.15M | 29M | 233K | 13.59M |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 852K | -2.78M | 26K | -886K | -162K | -47K |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -27.85M | -16.16M | -32.75M | -48.13M | -52.47M | -35.76M |
| FCF Margin % | -28.45% | -34.98% | -12.05% | - | - | -34.79% |
| FCF Growth % | - | 0.42% | -1.03% | -0.47% | -0.09% | 0.32% |
| FCF per Share | -1.49 | -0.86 | -1.68 | -2.02 | -2.06 | -1.26 |
| FCF Conversion (FCF/Net Income) | 0.99x | 0.90x | 3.87x | 1.52x | 1.51x | 1.18x |
| Interest Paid | 0 | 0 | 285K | 730K | 4.18M | 0 |
| Taxes Paid | 0 | 0 | 73K | 48K | 35K | 0 |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -202.5% | -31.28% | -68.32% | -207.48% |
| Return on Invested Capital (ROIC) | - | - | -940.67% | -117.03% | -78.14% | -101.08% |
| Gross Margin | 100% | 100% | 100% | - | - | 100% |
| Net Margin | -2716.75% | -3615.37% | -306.63% | - | - | -2920.04% |
| Debt / Equity | - | - | - | 0.41x | 1.18x | 8.51x |
| Interest Coverage | -2706.50x | -133.42x | -110.73x | -59.24x | -13.00x | -10.59x |
| FCF Conversion | 0.99x | 0.90x | 3.87x | 1.52x | 1.51x | 1.18x |
| Revenue Growth | - | -52.81% | 488.1% | -100% | - | - |
Rani Therapeutics Holdings, Inc. (RANI) reported $1.2M in revenue for fiscal year 2024. This represents a 23% increase from $1.0M in 2019.
Rani Therapeutics Holdings, Inc. (RANI) grew revenue by 0.0% over the past year. Growth has been modest.
Rani Therapeutics Holdings, Inc. (RANI) reported a net loss of $28.3M for fiscal year 2024.
Rani Therapeutics Holdings, Inc. (RANI) has a return on equity (ROE) of -207.5%. Negative ROE indicates the company is unprofitable.
Rani Therapeutics Holdings, Inc. (RANI) had negative free cash flow of $27.8M in fiscal year 2024, likely due to heavy capital investments.